Aurora(US:ACB)2025-11-05 13:00Financial Performance - Net revenue reached $90.4 million, an 11% year-over-year increase[8] - Global medical cannabis net revenue grew by 15% year-over-year, reaching $70.5 million[8, 13] - Adjusted gross margin was 61%, a 700 bps year-over-year increase[8] - Adjusted EBITDA increased by 52% year-over-year to $15.4 million[8, 13] - Free cash flow was $(42) million, a $(16) million year-over-year decrease[8] Market Leadership and Expansion - The company holds the 1 market share in the Canadian medical cannabis market[25, 29] - International net revenue increased by 22% year-over-year, reaching $42.7 million[13] - The company maintains leadership positions in key global markets including Germany, Australia, Poland, and the UK[7, 29, 30] Strategic Focus and Assets - The company focuses on high-growth, high-margin global medical cannabis opportunities[7] - The company has a strong cash balance of $141.9 million and no cannabis business debt[13] - The company has leading cannabis manufacturing facilities with GMP certification[37] - Plant propagation net revenue increased by 34% year-over-year, reaching $11.6 million[13]